Toxic oil syndrome: a current clinical and epidemiologic summary, including comparisons with the eosinophilia-myalgia syndrome.
In the spring and summer of 1981, an epidemic of a new illness now referred to as the toxic oil syndrome occurred in central and northwestern Spain, resulting in some 20,000 cases, 12,000 hospital admissions and greater than 300 deaths in the 1st year of the epidemic. The initial onset of illness was usually acute, and patients presented primarily with a respiratory syndrome involving cough, fever, dyspnea, hypoxemia, pulmonary infiltrates and pleural effusions. While approximately 50% of patients recovered from this acute phase of the illness without apparent sequelae, the remaining patients developed an intermediate or chronic phase, or both, of illness involving severe myalgia, eosinophilia, peripheral nerve damage, sclerodermiform skin lesions, sicca syndrome, alopecia and joint contractures, among other findings. Epidemiologic and analytic chemical studies have clearly linked the toxic oil syndrome to the ingestion of oil mixtures containing rapeseed oil denatured with aniline. However, the precise identity of the etiologic agent within this oil has never been determined. Aniline itself did not cause the illness, but the causal agent may be a reaction product of aniline with some oil component. Although many aspects of disease activity in the involved patients have lessened with time, the ultimate consequences of their disease are not clear and are the subject of ongoing study. The recently described eosinophilia-myalgia syndrome in the United States clinically resembles the toxic oil syndrome.
Kilbourne
E M
EM
Centers for Disease Control, U.S. Department of Health and Human Services, Atlanta, Georgia.
Posada de la Paz
M
M
Abaitua Borda
I
I
Diez Ruiz-Navarro
M
M
Philen
R M
RM
Falk
H
H
D000814:Aniline Compounds; D001937:Brassica; D002318:Cardiovascular Diseases / Q000139:chemically induced; D004196:Disease Outbreaks; D004802:Eosinophilia / Q000139:chemically induced* / Q000453:epidemiology; D005229:Fatty Acids, Monounsaturated; D005260:Female; D006801:Humans; D008297:Male; D009135:Muscular Diseases / Q000139:chemically induced* / Q000453:epidemiology; D010938:Plant Oils / Q000506:poisoning*; D011041:Poisoning / Q000453:epidemiology; D000074262:Rapeseed Oil; D013030:Spain / Q000453:epidemiology; D014364:Tryptophan / Q000009:adverse effects*; D014481:United States / Q000453:epidemiology
D000814:Aniline Compounds; D005229:Fatty Acids, Monounsaturated; D010938:Plant Oils; D000074262:Rapeseed Oil; D014364:Tryptophan; C023650:aniline